Citizens Business Bank Sells 17,172 Shares of Guardant Health, Inc. (NASDAQ:GH)

Citizens Business Bank lessened its stake in shares of Guardant Health, Inc. (NASDAQ:GH) by 27.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 45,424 shares of the company’s stock after selling 17,172 shares during the quarter. Citizens Business Bank’s holdings in Guardant Health were worth $1,229,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of the stock. Vanguard Group Inc. boosted its position in Guardant Health by 1.4% in the third quarter. Vanguard Group Inc. now owns 10,950,230 shares of the company’s stock valued at $324,565,000 after buying an additional 146,902 shares in the last quarter. Baillie Gifford & Co. acquired a new position in shares of Guardant Health in the 4th quarter worth approximately $167,137,000. Jennison Associates LLC grew its position in Guardant Health by 27.1% during the 3rd quarter. Jennison Associates LLC now owns 1,890,884 shares of the company’s stock worth $56,046,000 after acquiring an additional 403,475 shares during the last quarter. Charles Schwab Investment Management Inc. increased its holdings in Guardant Health by 31.9% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,211,499 shares of the company’s stock valued at $35,909,000 after purchasing an additional 292,888 shares in the last quarter. Finally, Federated Hermes Inc. raised its position in Guardant Health by 22.1% in the 3rd quarter. Federated Hermes Inc. now owns 1,109,500 shares of the company’s stock valued at $32,886,000 after purchasing an additional 200,500 shares during the last quarter. Institutional investors and hedge funds own 92.60% of the company’s stock.

Guardant Health Trading Down 1.0 %

NASDAQ:GH traded down $0.19 during mid-day trading on Tuesday, hitting $18.00. The company had a trading volume of 1,168,510 shares, compared to its average volume of 1,865,512. The company has a debt-to-equity ratio of 7.18, a quick ratio of 6.24 and a current ratio of 6.54. Guardant Health, Inc. has a fifty-two week low of $15.81 and a fifty-two week high of $41.06. The firm has a market cap of $2.19 billion, a P/E ratio of -4.25 and a beta of 0.87. The business’s fifty day moving average is $18.65 and its two-hundred day moving average is $22.75.

Guardant Health (NASDAQ:GH) last announced its quarterly earnings results on Thursday, February 22nd. The company reported ($1.58) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.93) by ($0.65). Guardant Health had a negative net margin of 85.02% and a negative return on equity of 301.94%. The firm had revenue of $155.05 million during the quarter, compared to analyst estimates of $151.71 million. As a group, research analysts expect that Guardant Health, Inc. will post -3.49 earnings per share for the current year.

Insiders Place Their Bets

In other Guardant Health news, insider Kumud Kalia bought 2,187 shares of Guardant Health stock in a transaction on Monday, March 18th. The shares were purchased at an average cost of $17.82 per share, for a total transaction of $38,972.34. Following the completion of the acquisition, the insider now owns 12,722 shares in the company, valued at approximately $226,706.04. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 6.20% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently commented on GH. Canaccord Genuity Group decreased their target price on Guardant Health from $45.00 to $30.00 and set a “buy” rating on the stock in a report on Monday. Piper Sandler lowered their price objective on shares of Guardant Health from $40.00 to $30.00 and set an “overweight” rating for the company in a research report on Monday, February 26th. Craig Hallum began coverage on shares of Guardant Health in a research report on Wednesday, April 24th. They set a “buy” rating and a $28.00 target price on the stock. JPMorgan Chase & Co. lowered their price target on shares of Guardant Health from $60.00 to $45.00 and set an “overweight” rating for the company in a report on Friday, February 23rd. Finally, Guggenheim reaffirmed a “neutral” rating on shares of Guardant Health in a report on Friday, April 5th. Two investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. According to MarketBeat, Guardant Health presently has an average rating of “Moderate Buy” and an average price target of $37.91.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.